Updated on 23 August 2012
What is the demand for your custom developed products in Asia ? What has been the trend in the customer's demand?
With more and more companies working on bio-therapeutics, the number of products for which there are no general purification strategies is increasing. The trend we are seeing is that more companies are looking for product specific solutions. This eliminates the need for extensive process development and results in increased purity and yield. Discussions with companies in the APAC region are ongoing.
What are your plans for the Asian market? Are you planning to enter into Asia directly?
BAC already has some customers in the APAC market and sees strong focus on biosimilars as a great opportunity for further sales and development of products. BAC is continuously extending its pipeline of products for manufacturing of biopharmaceuticals such as, FSH, hGH, GCSF and many others could also be of interest to us in this region.
To further increase its presence in the APAC market, BAC is planning on attending multiple conferences in the area to create brand awareness, make use of region oriented marketing opportunities and in the future possibly open a sales office in Asia.
Currently, there are no concrete plans for setting up operations in Asia, but this may change in the future. An initial option would be to set up a sales office and more actively approach companies in the region.
How is the competition and what are your strategies to deal with the same?
BAC recently signed a deal and launched a number of products for high precision liquid chromatography (HPLC) applications with its partner, Life Technologies. BAC chose this partner for its worldwide reach and excellent quality standards. By combining BAC's CaptureSelect technology with Life Technologies' POROS media, the companies can now offer a unique solution for process analytical testing (PAT) to those companies working on antibodies and antibody fragments as well as those working on serum albumin fusion proteins.